Versor Investments LP Sells 26,964 Shares of Option Care Health, Inc. $OPCH

Versor Investments LP decreased its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 68.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,600 shares of the company’s stock after selling 26,964 shares during the period. Versor Investments LP’s holdings in Option Care Health were worth $350,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of OPCH. Bryce Point Capital LLC bought a new position in Option Care Health during the 3rd quarter valued at $687,000. Johnson Investment Counsel Inc. raised its holdings in shares of Option Care Health by 25.5% in the third quarter. Johnson Investment Counsel Inc. now owns 110,992 shares of the company’s stock valued at $3,081,000 after purchasing an additional 22,536 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in shares of Option Care Health by 23.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 55,429 shares of the company’s stock valued at $1,539,000 after purchasing an additional 10,512 shares during the last quarter. Hantz Financial Services Inc. lifted its position in shares of Option Care Health by 987.7% during the third quarter. Hantz Financial Services Inc. now owns 1,414 shares of the company’s stock valued at $39,000 after purchasing an additional 1,284 shares in the last quarter. Finally, Cornerstone Planning Group LLC boosted its holdings in Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after purchasing an additional 1,067 shares during the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on OPCH shares. National Bank Financial set a $37.00 price objective on shares of Option Care Health in a research note on Tuesday, January 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $37.00 target price on shares of Option Care Health in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Option Care Health in a report on Monday, December 29th. Citizens Jmp restated a “market outperform” rating and issued a $38.00 price objective (up previously from $36.00) on shares of Option Care Health in a research note on Tuesday, January 13th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Option Care Health in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Option Care Health currently has a consensus rating of “Moderate Buy” and an average target price of $37.46.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $35.42 on Friday. The company has a current ratio of 1.56, a quick ratio of 1.05 and a debt-to-equity ratio of 0.85. The stock has a fifty day simple moving average of $33.61 and a two-hundred day simple moving average of $30.17. Option Care Health, Inc. has a 1-year low of $24.24 and a 1-year high of $36.80. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of 28.11, a price-to-earnings-growth ratio of 2.06 and a beta of 0.84.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.